TapewireFind a company

person · Reporting owner

Thompson Travis Alvin

Disclosed activity across 1 company

Tapewire entity
29666
SEC CIK
0001983944

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BICYCLE THERAPEUTICS PLCBCYC · Entity 5993Chief Financial OfficerOctober 02, 2026October 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BICYCLE THERAPEUTICS PLC

Report date October 02, 2026 · Filed October 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect64,449 Ending reported balance After 2026-10-05 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-02 · Sale · Disposed 893 · Balance 64,528

F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 2 · 2026-10-05 · Sale · Disposed 79 · Balance 64,449

F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 05, 2026 Filed Oct 6, 2026 20:34 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 79 $3.57 $282.03
Disclosure

SEC source: 0001983944-26-000014 · form4-10062026_081052.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,449

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 02, 2026 Filed Oct 6, 2026 20:34 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 893 $3.47 $3,098.71
Disclosure

SEC source: 0001983944-26-000014 · form4-10062026_081052.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,528

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 15, 2026 Filed Jul 17, 2026 20:15 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantEmployee Stock Option (right to buy) · Derivative 60,000 $0.00 Strike: $4.21 $0.00
Disclosure

SEC source: 0001983944-26-000010 · form4-07172026_040708.xml · derivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Ordinary Shares · 60,000 shares

Expires 2036-07-15

F1 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on July 15, 2027 and the remaining shares in 36 equal monthly installments thereafter.

Read SEC document
July 06, 2026 Filed Jul 7, 2026 21:00 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 104 $4.31 $448.24
Disclosure

SEC source: 0001983944-26-000008 · form4-07072026_050702.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,441

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.31 inclusive.

Read SEC document
July 02, 2026 Filed Jul 7, 2026 21:00 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 819 $4.27 $3,497.13
Disclosure

SEC source: 0001983944-26-000008 · form4-07072026_050702.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,545

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Read SEC document
April 06, 2026 Filed Apr 6, 2026 22:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 102 $5.05 $515.10
Disclosure

SEC source: 0001983944-26-000006 · form4-04062026_060407.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,364

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

Read SEC document
April 02, 2026 Filed Apr 6, 2026 22:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 799 $4.91 $3,923.09
Disclosure

SEC source: 0001983944-26-000006 · form4-04062026_060407.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,466

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $4.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 03, 2026 Filed Feb 5, 2026 00:01 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantEmployee Stock Option (right to buy) · Derivative 58,000 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0001983944-26-000004 · form4-02052026_120235.xml · derivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,000

Underlying: Ordinary Shares · 58,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on February 3, 2027 and the remaining shares in 36 equal monthly installments thereafter.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 01:00 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 1,115 $6.45 $7,191.75
Disclosure

SEC source: 0001983944-26-000002 · form4-01062026_080126.xml · nonDerivative · entry 3

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,265

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive.

Read SEC document
January 02, 2026 Filed Jan 7, 2026 01:00 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantEmployee Stock Option (right to buy) · Derivative 75,000 $0.00 Strike: $7.08 $0.00
Disclosure

SEC source: 0001983944-26-000002 · form4-01062026_080126.xml · derivative · entry 4

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Ordinary Shares · 75,000 shares

Expires 2036-01-02

F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter.

Read SEC document
January 02, 2026 Filed Jan 7, 2026 01:00 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 1,317 $6.80 $8,955.60
Disclosure

SEC source: 0001983944-26-000002 · form4-01062026_080126.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,380

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5).

Read SEC document
January 02, 2026 Filed Jan 7, 2026 01:00 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantOrdinary Shares 37,500 $0.00 $0.00
Disclosure

SEC source: 0001983944-26-000002 · form4-01062026_080126.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,697

F1 · shares: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

Read SEC document
October 03, 2025 Filed Oct 6, 2025 20:45 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 103 $8.41 $866.23
Disclosure

SEC source: 0001983944-25-000003 · form4-10062025_041003.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,197

F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.40 to $8.50 inclusive.

Read SEC document
October 02, 2025 Filed Oct 6, 2025 20:45 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 221 $8.40 $1,856.40
Disclosure

SEC source: 0001983944-25-000003 · form4-10062025_041003.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,300

F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.37 to $8.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Read SEC document
July 03, 2025 Filed Jul 7, 2025 21:20 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 100 $7.44 $744.00
Disclosure

SEC source: 0001415889-25-019424 · form4-07072025_050703.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,521

F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.405 to $7.483 inclusive.

Read SEC document
July 02, 2025 Filed Jul 7, 2025 21:20 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 206 $7.09 $1,460.54
Disclosure

SEC source: 0001415889-25-019424 · form4-07072025_050703.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,621

F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.09 to $7.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Read SEC document
April 03, 2025 Filed Apr 4, 2025 21:35 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 109 $7.48 $815.32
Disclosure

SEC source: 0001415889-25-010240 · form4-04042025_050401.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,827

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.45 to $7.50 inclusive.

Read SEC document
April 02, 2025 Filed Apr 4, 2025 21:35 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 210 $8.02 $1,684.20
Disclosure

SEC source: 0001415889-25-010240 · form4-04042025_050401.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,936

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Read SEC document
January 06, 2025 Filed Jan 7, 2025 00:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 2,686 $15.00 $40,290.00
Disclosure

SEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 4

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,146

F6 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 00:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 159 $14.75 $2,345.25
Disclosure

SEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 3

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,832

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.69 to $14.75 inclusive.

Read SEC document
January 02, 2025 Filed Jan 7, 2025 00:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantEmployee Stock Option (right to buy) · Derivative 43,500 $0.00 Strike: $14.00 $0.00
Disclosure

SEC source: 0001415889-25-000928 · form4-01062025_070128.xml · derivative · entry 5

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,500

Underlying: Ordinary Shares · 43,500 shares

Expires 2035-01-02

F7 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter.

Read SEC document
January 02, 2025 Filed Jan 7, 2025 00:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 1,750 $14.09 $24,657.50
Disclosure

SEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,991

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5).

Read SEC document
January 02, 2025 Filed Jan 7, 2025 00:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantOrdinary Shares 17,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,741

F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,109 $0.00 Strike: $9.82 $0.00
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 12

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,954

Underlying: Ordinary Shares · 1,109 shares

Expires 2029-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F7 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 154 $0.00 Strike: $8.21 $0.00
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 11

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 302

Underlying: Ordinary Shares · 154 shares

Expires 2029-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024.

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F7 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,312 $0.00 Strike: $1.87 $0.00
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 10

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,617

Underlying: Ordinary Shares · 1,312 shares

Expires 2028-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024.

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F7 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 231 $24.82 $5,733.42
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 9

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,241

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $24.825 inclusive.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 209 $24.77 $5,176.93
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 8

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,472

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.73 to $24.81 inclusive.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 3,241 $25.21 $81,705.61
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 7

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,681

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 1,109 $25.05 $27,780.45
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 6

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,922

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6).

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 Exercise / conversionOrdinary Shares 1,109 $9.82 $10,890.38
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 5

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 154 $25.01 $3,851.54
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 4

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,922

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.08 inclusive.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 Exercise / conversionOrdinary Shares 154 $8.21 $1,264.34
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 3

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024.

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 1,312 $25.05 $32,865.60
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,922

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6).

Read SEC document
November 11, 2024 Filed Nov 14, 2024 00:43 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 Exercise / conversionOrdinary Shares 1,312 $1.87 $2,453.44
Disclosure

SEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024.

F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024.

Read SEC document
October 03, 2024 Filed Oct 4, 2024 20:50 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 153 $22.26 $3,405.78
Disclosure

SEC source: 0001415889-24-024767 · form4-10042024_041001.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,922

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 03, 2024 Filed Jul 8, 2024 22:55 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 148 $19.64 $2,906.72
Disclosure

SEC source: 0001415889-24-019387 · form4-07082024_060709.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,075

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 03, 2024 Filed Apr 5, 2024 20:30 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 152 $23.81 $3,619.12
Disclosure

SEC source: 0001415889-24-010413 · form4-04052024_040425.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,223

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 03, 2024 Filed Jan 4, 2024 23:36 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 604 $17.50 $10,570.00
Disclosure

SEC source: 0001209191-24-000890 · doc4.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,375

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 23:36 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantEmployee Stock Option (right to buy) · Derivative 31,000 $0.00 Strike: $18.08 $0.00
Disclosure

SEC source: 0001209191-24-000890 · doc4.xml · derivative · entry 3

Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Ordinary Shares · 31,000 shares

Expires 2034-01-02

F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 23:36 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 GrantOrdinary Shares 16,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-000890 · doc4.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,979

F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

Read SEC document
October 03, 2023 Filed Oct 5, 2023 21:50 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 54 $20.00 $1,080.00
Disclosure

SEC source: 0001209191-23-052254 · doc4.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,979

F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 to $20.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 20:57 UTC BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 SaleOrdinary Shares 61 $25.10 $1,531.10
Disclosure

SEC source: 0001209191-23-041578 · doc4.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,033

F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.